Screened 2026-09-08 · the tape above runs as of 13:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Keysight Technologies holds its Markup at $333.42. Consolidating, no directional conviction, held for 39 days.
As held on the ledger · 2026-09-08
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 39 days
Price at the screen
$333.42
Valuation
45.12 trailing · 24.43 forward price to earnings
Values screen
PASS· score 79.0
Beta
1.21
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
24.58%
Below 33%
Interest-bearing debt is just 24.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
1.87%
Below 33%
Cash held in interest-bearing accounts and securities is 1.9% of assets, under the one-third limit.
Pass
Receivables
24.88%
Below 49%
Money owed to the company is 24.9% of assets, under the 49% limit.
Pass
Revenue purity
1.90%
Below 5%
Only 1.9% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OVERVALUED: it trades at roughly a 16% discount to our $386.20 fair value, moderate competitive moat, 36.50% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 15.8% margin of safety to the base estimate.
Third-party analyst targets: 12 covering, consensus Buy. The average target sits +25% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Test gear that quietly powers every gadget
Every time a 5G base station fires up or an electric car rolls off the line, Keysight's boxes sit in the background checking the signals. The firm posts 32% revenue growth, 17% profit margins and an 18% return on equity, all while clearing our ethical screen without a mark.
Yet the shares trade at a forward multiple of 26.6 times earnings against a price already 12% above our fair value. Analyst targets sit higher still, but those numbers bake in continued expansion that looks stretched once growth normalises. Moderate competitive edge offers little cushion if the multiple contracts.
Valuation leaves little room for disappointment in a sector tied to capital spending cycles. Currency swings and slower telecom roll-outs could trim results faster than the multiple suggests. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
KEYS trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 54% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 98%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (13 analysts) rates it buy, with a mean price target of $383.
2026-08-18Markup$336.02+0.0%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 54% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 98%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (13 analysts) rates it buy, with a mean price target of $383. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-16Markup · changed$336.02+7.1%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 54% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 98%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (13 analysts) rates it buy, with a mean price target of $383. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.9% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 54% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 98%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (13 analysts) rates it buy, with a mean price target of $383.
2026-07-18Markup$329.83+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 54% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 98%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (13 analysts) rates it buy, with a mean price target of $383.
2026-07-03Markup$329.83+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$329.83Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
